ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock News
NASDAQ:ADPT - Nasdaq - US00650F1093 - Common Stock - Currency: USD
ADPT Latest News, Press Relases and Analysis
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®
clonoSEQ® is now integrated into Flatiron Health’s OncoEMR®, simplifying MRD testing access for over 4,500 clinicians across the Flatiron network....
Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, Craig-Hallum began coverage of Adaptive Biotechnologies Corporation (NASDAQ:ADPT)’s stock with a “Buy” rating and a price objective of $15, as reported by The Fly. The research firm believes that the company is an unequivocal leader in […]
Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?
Smart Beta ETF report for FYC
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers...
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancers
SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal
SPRO shares surge after GSK-partnered oral drug hits phase III goal early, paving the way for FDA filing and a shift in cUTI treatment options.
U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot
The government scraps funding deal for MRNA's bird flu shot, despite encouraging safety and efficacy data from early clinical studies on the vaccine.
Why Riot Platforms, Inc. (RIOT) Went Down On Wednesday
We recently published a list of 10 Stocks Crash Harder Than Wall Street. In this article, we are going to take a look at where Riot Platforms, Inc. (NASDAQ:RIOT) stands against other worst-performing stocks. Riot Platforms dropped its share prices by 8.32 percent on Wednesday to close at $8.38 apiece as investor sentiment was dampened by […]
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to...
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Is Adaptive Biotechnologies (ADPT) Outperforming Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and CVS Health (CVS) have performed compared to their sector so far this year.
Mentions: CVS
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
Style Box ETF report for FYC
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz
BMRN's acquisition of INZY is set to add a late-stage enzyme replacement therapy for a rare genetic condition. The deal is likely to be closed by September.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer
Following the approval, ABBV's Emrelis becomes the first FDA-approved therapy for previously treated advanced NSCLC patients with high c-Met protein overexpression.
Allogene's Q1 Earnings In Line With Estimates, Sales Nil
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter.
Insmed's Q1 Loss Wider Than Expected, Sales Match Estimates
INSM posts wider-than-expected loss in the first quarter. It reiterates the 2025 sales outlook for Arikayce in the range of $405-$425 million.
Adaptive Biotechnologies (ADPT) is a Great Momentum Stock: Should You Buy?
Does Adaptive Biotechnologies (ADPT) have what it takes to be a top stock pick for momentum investors? Let's find out.
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up
Novavax posts encouraging first-quarter results on the back of an additional $603 million in revenues recognized from the termination of two advanced purchase agreements.
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut
IOVA reports dismal first-quarter results. The share price plunges after the company significantly lowers its 2025 sales guidance.
Does Adaptive Biotechnologies (ADPT) Have the Potential to Rally 26.45% as Wall Street Analysts Expect?
The consensus price target hints at a 26.5% upside potential for Adaptive Biotechnologies (ADPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Has Adaptive Biotechnologies (ADPT) Outpaced Other Medical Stocks This Year?
Here is how Adaptive Biotechnologies (ADPT) and Centene (CNC) have performed compared to their sector so far this year.
Mentions: CNC
Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Tops Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 28.57% and 21.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: QGEN
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage...
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results
OpenAI And Andreessen Horowitz Lead $43M Round For Cybersecurity Startup Taking On AI Scammers, Deepfakes, And Voice Spoofs
Adaptive Security, a New York-based cybersecurity firm, has successfully raised $43 million in a Series A funding round. According to Inc., this round was co-led by OpenAI‘s Startup Fund and venture capital firm Andreessen Horowitz, marking OpenAI’s inaugural investment in the cybersecurity sector. Other participants included Abstract Ventures, Eniac Ventures, CrossBeam Ventures, and K5, along with executives from companies such as Alphabet (NASDAQ:GOOG, GOOGL)), Workday (NASDAQ:WDAY), Shopify (